NCT05043376View on ClinicalTrials.gov

Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Hospitalised Patients (Non-ICU) With COVID-19

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

November 21, 2021

Study Completion Date

November 21, 2021

Conditions

Covid19

Interventions

DRUG

Standard of care

Standard COVID-19 care as per the hospital guidelines

DIETARY_SUPPLEMENT

BLIS K12

Daily 2 oral BLIS K12 tablets for up to 14 days.

Trial Locations (1)

54000

King Edward Medical University Teaching Hospital, Lahore

All Listed Sponsors

lead

King Edward Medical University

OTHER

NCT05043376 - Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Hospitalised Patients (Non-ICU) With COVID-19 | Biotech Hunter | Biotech Hunter